Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Stratatech Corporation
Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
StrataGraft Topical Burn Treatment Gets US FDA Approval
The topical treatment is made from human skin cells and can be applied to speed the healing of deep thermal burns.
Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.